Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...

The decision to expand the trial was made following the completion of monotherapy dose escalation for SON-1010.

Love is 'an ever-fixèd mark.' Kate Moncrief and Brendon Fox - No impediments to this marriage of true minds, true love ...

(RTTNews) - Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage biotechnology company, announced on Tuesday the granting of a new European patent for its Fully Human Albumin Binding or ...

Sonnet's F H AB platform consists of a single, fully human construct of a F H AB antibody fragment that has high affinity to bind to human albumin. The platform provides an off-the-shelf lock and load ...

The company claims its newly upgraded model is number one in user satisfaction and speed - but its methodology is unclear.

PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing ...

Sonnet has a new Thunderbolt 5 dock with four TB5 ports and an internal PCIe 4.0 NVMe SSD slot that'll work with your existing M-series Macs and ensure future compatibility with higher speeds.

The upgraded Claude 3.5 Sonnet, the latest and most intelligent model in the Claude model family from artificial intelligence (AI) safety and research company Anthropic, is now generally available on ...